Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...
Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...
Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against their ...
A so-called 'miracle' Alzheimer's drug caused brain bleeds in more than a third of patients, a new study has revealed.
Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
Vaccinex went public in 2018, raising around $40m to advance its pipeline of neurodegenerative disease therapies. The initial ...